Ischemix
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
13 Pullard Rd Unit 39, Grafton, Massachu...Phone Number
(508) 839-2999Website
www.ischemix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Ischemix
Ischemix, Inc. specializes in developing novel cytoprotective compounds, particularly targeting serious diseases. Their lead product candidate, CMX-2043, is currently in preclinical development for traumatic brain injury (TBI) and has shown promising results in various preclinical studies. The company focuses on expanding the therapeutic applications of CMX-2043, which possesses multi-modal activity effective for complex TBI conditions. Ischemix holds several patents related to the composition and usage of CMX-2043 worldwide.Explore more
Ischemix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ischemix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Ischemix has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Ischemix
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ischemix launches new products
Ischemix, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ischemix recently announced quarterly report
Funding: Get notified immidiatlly once Ischemix has new funding data
Check out if Ischemix is spiking on competitors!
Click to see if Ischemix had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Ischemix
Find 2 more new buyers
Compare Similar Companies to Ischemix
Compare insights from companies similar to Ischemix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ischemix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ischemix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ischemix.
Ischemix financials insights
Gather financial insights about Ischemix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$6.6M
Ischemix Tech Stack
A closer look at the technologies used by Ischemix
Ischemix News & Media
Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial
CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translational studies. CMX-2043 will be Phase 2-ready by the first quarter of 2024.Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
Novel, proprietary drug candidate has shown therapeutic potential in extensive preclinical studies Novel, proprietary drug candidate has shown therapeutic potential in extensive preclinical studiesNovel compound for treatment of traumatic brain injury (TBI) demonstrates positive results in a preclinical study
Strongest announced preclinical results of any drug candidate currently in development for TBI
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Ischemix
Sign Up For FreeTo access detailed company insights
Ischemix, Inc. specializes in developing novel cytoprotective compounds, particularly targeting serious diseases. Their lead product candidate, CMX-2043, is currently in preclinical development for traumatic brain injury (TBI) and has shown promising results in various preclinical studies. The company focuses on expanding the therapeutic applicatio... Read More
